CoChat

Effect of 3BNC117 and romidepsin on the HIV-1 reservoir in people taking suppressive antiretroviral therapy (ROADMAP): a randomised, open-label, phase 2A trial

Open access
Gruell, Henning, Gunst, Jesper D, Cohen, Yehuda Z, Pahus, Marie H, Malin, Jakob J, Platten, Martin, Millard, Katrina G, Tolstrup, Martin, Jones, R Brad, Conce Alberto, Winnifer D, Lorenzi, Julio C C, Oliveira, Thiago Y, Kümmerle, Tim, Suárez, Isabelle, Unson-O'Brien, Cecilia, Nogueira, Lilian, Olesen, Rikke, Østergaard, Lars, Nielsen, Henrik, Lehmann, Clara, Nussenzweig, Michel C, Fätkenheuer, Gerd, Klein, Florian, Caskey, Marina, Søgaard, Ole S · 2022 · The Lancet Microbe
Cited by 82

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

Abstract

Background The administration of broadly neutralising anti-HIV-1 antibodies before latency reversal could facilitate elimination of HIV-1-infected CD4 T cells.We tested this concept by combining the broadly neutralising antibody 3BNC117 in combination with the latency-reversing agent romidepsin in people with HIV-1 who were taking suppressive antiretroviral therapy (ART).Methods We did a randomised, open-label, phase 2A trial at three university hospital centres in Denmark, Germany, and the USA.Eligible participants were virologically suppressed adults aged 18-65 years who were infected with HIV-1 and on ART for at least 18 months, with plasma HIV-1 RNA concentrations of less than 50 copies per mL for at least 12 months, and a CD4 T-cell count of greater than 500 cells per µL.Participants were randomly assigned (1:1) to receive 3BNC117 plus romidepsin or romidepsin alone in two cycles.All participants received intravenous infusions of romidepsin (5 mg/m² given over 120 min) at weeks 0, 1, and 2 (treatment cycle 1) and weeks 8, 9, and 10 (treatment cycle 2).Those in the 3BNC117 plus romidepsin group received an intravenous infusion of 3BNC117 (30 mg/kg given over 60 min) 2 days before each treatment cycle.An analytic treatment interruption (ATI) of ART was done at week 24 in both groups.Our primary endpoint was time to viral rebound during analytic treatment interruption, which was assessed in all participants who completed both treatment cycles and ATI.We used a log-rank test to compare time to viral rebound during analytic treatment interruption between the two groups.This trial is registered with ClinicalTrials.gov, NCT02850016.It is closed to new participants, and all follow-up is complete.Findings Between March 20, 2017, and Aug 14, 2018, 22 people were enrolled and randomly assigned, 11 to the 3BNC117 plus romidepsin group and 11 to the romidepsin group.19 participants completed both treatment cycles and the ATI: 11 in the 3BNC117 plus romidepsin group and 8 in the romidepsin group.The median time to viral rebound during ATI was 18 days (IQR 14-28) in the 3BNC117 plus romidepsin group and 28 days (21-35) in the romidepsin group B (p=0•0016).Although this difference was significant, prolongation of time to viral rebound was not clinically meaningful in either group.All participants in both groups reported adverse events, but overall the combination of 3BNC117 and romidepsin was safe.Two severe adverse events were observed in the romidepsin group during 48 weeks of follow-up, one of which-increased direct bilirubin-was judged to be related to treatment.Interpretation The combination of 3BNC117 and romidepsin was safe but did not delay viral rebound during analytic treatment interruptions in individuals on long-term ART.The results of our trial could serve as a benchmark for further optimisation of HIV-1 curative strategies among people with HIV-1 who are taking suppressive ART.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/s2666-5247(21)00239-1

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 3 references

Cited by

See all 82

Metadata

Authors
Gruell, H., Gunst, J. D., Cohen, Y. Z., Pahus, M. H., Malin, J. J., Platten, M., Millard, K. G., Tolstrup, M., Jones, R. B., Conce Alberto, W. D., Lorenzi, J. C. C., Oliveira, T. Y., Kümmerle, T., Suárez, I., Unson-O'Brien, C., Nogueira, L., Olesen, R., Østergaard, L., Nielsen, H., Lehmann, C., Nussenzweig, M. C., Fätkenheuer, G., Klein, F., Caskey, M., & Søgaard, O. S.
Venue
The Lancet Microbe
Publisher
Elsevier BV
Published
2022-03
Volume
3
Issue
3
Pages
e203-e214
ISSN
2666-5247 (ISSN-L)
OpenAlex
W4207008834
Cited by
82
References
3
FWCI
4.88
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Effect of 3BNC117 and romidepsin on the HIV-1 reservoir in people taking suppressive antiretroviral therapy (ROADMAP): a randomised, open-label, phase 2A trial. https://app.cochat.ai/papers/10.1016/s2666-5247(21)00239-1
The paper
Gruell, H., Gunst, J. D., Cohen, Y. Z., Pahus, M. H., Malin, J. J., Platten, M., Millard, K. G., Tolstrup, M., Jones, R. B., Conce Alberto, W. D., Lorenzi, J. C. C., Oliveira, T. Y., Kümmerle, T., Suárez, I., Unson-O'Brien, C., Nogueira, L., Olesen, R., Østergaard, L., Nielsen, H., . . . Søgaard, O. S. (2022). Effect of 3BNC117 and romidepsin on the HIV-1 reservoir in people taking suppressive antiretroviral therapy (ROADMAP): a randomised, open-label, phase 2A trial. The Lancet Microbe. https://doi.org/10.1016/s2666-5247(21)00239-1

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.